News Releases

Davos Life Science Announces Issuance of Patent Covering its Proprietary Formulation Bio-Enhanced 20

Davos Life Science is pleased to announce the issuance of patents covering the “Formulation for Effective Tocotrienol Delivery”.

Company Logo

Released By KLK OLEO

Davos Life Science is pleased to announce the issuance of the following patents covering the “Formulation for Effective Tocotrienol Delivery”:

Australian Patent No. 2015354848
Indian Patent No. 331319
Japan Patent No. 6675413
New Zealand Patent No. 731986
US Patent No. 10,493,055

The patented formulation covers a self-emulsifying drug delivery formulation for improved delivery of Tocotrienols.


This formulation shows an improved bioavailability of Tocotrienols. Davos Life Science commissioned an opened-label, randomised, 4-way cross-over clinical study to compare the bioavailability of DavosLife E3 Bio-Enhanced 20 with a market sample. This study was conducted on 28 healthy volunteers with a dosage of 200 mg Tocotrienols. DavosLife E3 Bio-Enhanced 20 was found to offer 46% higher bioavailability compared to a market sample. Learn more.

Visit www.klkoleo.com/davoslife/patents for details.

Request more information from KLK OLEO

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters